• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

DF/HCC Announcements

September 17, 2014

Seminars in Oncology: "Chromatin Regulation: New Methods and Concepts"

Guest Speaker: Gerald Crabtree, MDProfessor, Pathology & Developmental BiologyStanford UniversityStanford, CA Tuesday, September 23, 2014, 4PM Jimmy Fund Auditorium Hosted by: Charles Roberts, MD, PhD[more]

September 07, 2014

Lung Cancer Developmental Research Project Award – Request for Applications

The Dana-Farber/Harvard Cancer Center Specialized Program in Research Excellence (SPORE) in Lung Cancer seeks applications for Developmental Research Project Awards in Lung Cancer Research. The funding for these awards will come...[more]

July 30, 2014

2014 Student Scientific Presentations - DF/HCC CURE Research Training Program

The Continuing Umbrella of Research Experiences (CURE) Program of DF/HCC invites you to attend the end-of-summer student research presentations on August 12, 13, and 14, 2014.[more]

July 29, 2014

Boston Area Gene Expression Meeting 2014

Boston Area Gene Expression Meeting 2014 Tuesday, August 5, 20149:00 am -­‐ 6:00 pmJaharis Auditorium, Tufts Medical School150 Harrison Ave., Boston, MA No Registration Required Organizers: Steve Buratowski and Ananda...[more]

July 16, 2014

The DF/HCC High-Throughput Polymorphism Detection Core adds targeted sequencing service

The DF/HCC High Throughput Polymorphism Core / Partners HealthCare | Personalized Medicine TaqMan genotyping core is pleased to announce a new service. The Core is offering a targeted sequencing service using the Ion...[more]

July 16, 2014

Cancer Research Network Scholars Program: Call for Applications

Deadline to submit required Letter of Intent:  September 15, 2014Upon invitation, deadline to submit Full Application:  December 1, 2014 The Cancer Research Network announced its Call for Applications for the CRN...[more]

July 01, 2014

NCCN Request for Proposals (RFP): Phase I/II Clinical Trials and Pre-Clinical Trials of Enzalutamide for Selected Cancers

The National Comprehensive Cancer Network® (NCCN®) has received a research grant from Astellas Pharma, Inc. and Medivation, Inc. to support NCCN investigator initiated clinical and pre-clinical studies of enzalutamide...[more]

Displaying results 43 to 49 out of 597